The following is an excerpt.
BANGALORE: India’s biotechnology and healthcare services sector says numerous regulatory challenges are thwarting discovery, research and innovation. Kiran Mazumdar Shaw, CMD of the Rs 1,600-crore biotech firm Biocon , and Dr Karen Bernstein, co-founder and chairman of BioCentury, US, a global provider of biopharma analysis, research and data, share their thoughts.
View the original article here: Clinical trials, GM crops can only do India good: Experts
 |
Infographics | More... |
Is tilapia a human-made freak that we should avoid — or an evolutionary rockstar? 
Viewpoint: Debunking organic food myths again… and again 
25 years of GMO crops: Economic, environmental and human health benefits 
Viewpoint: By engineering block on Vitamin A enhanced Golden Rice, Greenpeace ‘puts the whole environmental movement into disrepute’ 
Marrying your cousin? There may be evolutionary benefits 
Viewpoint: Should you be concerned when you read that a chemical in your food has been linked to cancer? Here’s an epidemiologist’s checklist to detect over-hyped scares 
KFC developing world’s first bioprinted chicken nuggets for planned rollout in Russia in fall 2020 
Viewpoint: The organic food industry is a $180 billion marketing fraud 
How Wegovy and Ozempic could transform our food systems 
Why humans have larger penises and smaller testicles than other great apes 
